ABVX
Abivax SA
NASDAQ · Healthcare · Biotechnology · FR
$88.13
−4.60%Price chart
Sep 17Sep 22Sep 25Sep 30Oct 5Oct 8Oct 13Oct 16
Key dataOct 16, 2026
Open$90.82
From 52W high−39.35%
Volume1.30M
Market cap$7.69B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 16, 2026
Open
$90.82
From 52W high
−39.35%
Volume
1.30M
Market cap
$7.69B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−17.0x
P/E (TTM)
—
RSI (14)
38.3
MomentumView details →
1D Return
−4.60%
YTD Return
−34.17%
SummaryUpdated Jun 1, 2026
ABIVAX SA (NASDAQ:ABVX) is a French biotechnology company founded in 2013 and headquartered in Paris. The company went public on the NASDAQ in October 2023, making it a relatively new entrant to the U.S. public markets. ABIVAX focuses on discovering and developing innovative drugs for treating inflammatory diseases, infectious diseases, and cancer. As a clinical-stage biopharmaceutical company, ABIVAX is currently advancing multiple drug candidates through various phases of clinical trials, with its lead compound ABX464 showing promise in treating autoimmune and inflammatory conditions.
Similar companies
Latest newsMore news →
Abivax SA announced that Chris Rabbat will succeed Fabio Cataldi as Chief Medical Officer and Tim Kelly was appointed Chief Technical Officer.25d agoAbivax SA reported its financial results for the first half of 2026, with cash, cash equivalents and short-term investments of €402.4 million as of June 30, 2026.25d agoAbivax SA is scheduled to release its first-half earnings report after the closing bell on Monday, Sept. 21.33d ago